Analysts Set KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Price Target at $25.00

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have been assigned an average rating of “Buy” from the seven research firms that are covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $23.80.

KALV has been the topic of a number of research reports. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. JMP Securities began coverage on shares of KalVista Pharmaceuticals in a research note on Friday, January 31st. They set an “outperform” rating and a $19.00 price target on the stock. TD Cowen started coverage on KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price objective for the company. Bank of America assumed coverage on KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They set a “buy” rating and a $22.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th.

Insider Activity at KalVista Pharmaceuticals

In other news, insider Paul K. Audhya sold 8,077 shares of the firm’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $74,793.02. Following the completion of the transaction, the insider now owns 94,199 shares in the company, valued at $872,282.74. This trade represents a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Benjamin L. Palleiko sold 14,400 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $133,344.00. Following the completion of the sale, the chief executive officer now owns 266,598 shares in the company, valued at $2,468,697.48. This represents a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,291 shares of company stock valued at $304,086. 10.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. raised its holdings in shares of KalVista Pharmaceuticals by 67.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock worth $96,000 after acquiring an additional 3,328 shares in the last quarter. Intech Investment Management LLC purchased a new stake in KalVista Pharmaceuticals during the third quarter valued at $126,000. SG Americas Securities LLC bought a new position in KalVista Pharmaceuticals during the third quarter valued at $153,000. Quest Partners LLC bought a new position in KalVista Pharmaceuticals during the third quarter valued at $175,000. Finally, The Manufacturers Life Insurance Company grew its stake in shares of KalVista Pharmaceuticals by 27.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock worth $182,000 after buying an additional 3,314 shares in the last quarter.

KalVista Pharmaceuticals Trading Down 2.8 %

Shares of KALV opened at $9.62 on Friday. The firm has a fifty day simple moving average of $8.80 and a two-hundred day simple moving average of $10.76. The firm has a market cap of $475.40 million, a PE ratio of -2.64 and a beta of 0.85. KalVista Pharmaceuticals has a 1-year low of $7.30 and a 1-year high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.01. As a group, research analysts forecast that KalVista Pharmaceuticals will post -3.56 EPS for the current fiscal year.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).